The aim of this study was to investigate the effect of the GP IIb/IIIa inhibitor abciximab (ReoPro((R))) on the function and interaction of platelets and leukocytes during experimental CPB.
The incidence of vascular access site related complications ranges between 0.8 % to 1.8 % of diagnostic cardiac catheterization and up to 9 % of percutaneous coronary interventions.
